LY3832479

DRUG3 trials

Sponsors

Eli Lilly and Company

Conditions

COVID-19Healthy

Phase 1

A Study of LY3832479 (LY-CoV016) in Healthy Participants

CompletedNCT04441931

Eli Lilly and CompanyHealthy

Start: 2020-06-19End: 2020-10-02Updated: 2021-12-06

A Study of LY3832479 (LY-CoV016) in Healthy Participants 1

CompletedNCT04611789

Eli Lilly and CompanyHealthy

Start: 2020-11-02End: 2021-02-10Updated: 2021-12-06

Phase 2

A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness

CompletedNCT04427501

Eli Lilly and CompanyCOVID-19

Start: 2020-06-17End: 2023-02-21Updated: 2024-04-11

Related Papers

The Safety and Pharmacokinetics of the Neutralizing Monoclonal Antibody Bebtelovimab in Pediatric Patients with Mild-to-Moderate COVID-19 to Inform Pandemic Preparedness

Open Forum Infectious Diseases2025-11-20

Efficacy and Safety of Low-Dose, Rapidly Infused Bamlanivimab and Etesevimab: Phase 3 BLAZE-1 Trial for Mild-to-Moderate COVID-19.

2024-09-041 citations

Pharmacokinetics, Efficacy, and Safety of a SARS-CoV-2 Antibody Treatment in Pediatric Participants: An Open-Label Addendum of a Placebo-Controlled, Randomized Phase 2/3 Trial

Infectious Diseases and Therapy2023-06-171 citations

Bamlanivimab and Etesevimab Improve Symptoms and Associated Outcomes in Ambulatory Patients at Increased Risk for Severe Coronavirus Disease 2019: Results From the Placebo-Controlled Double-Blind Phase 3 BLAZE-1 Trial

Open Forum Infectious Diseases2022-04-0710 citations

A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load

Clinical Infectious Diseases2021-10-2768 citations

A Narrative Review of the Clinical Practicalities of Bamlanivimab and Etesevimab Antibody Therapies for SARS-CoV-2.

2021-08-1029 citations

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19

New England Journal of Medicine2021-07-14654 citations

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19

JAMA2021-01-21931 citations

Safety, tolerability, pharmacokinetic characteristics, and immunogenicity of MW33: a Phase 1 clinical study of the SARS-CoV-2 RBD-targeting monoclonal antibody

Emerging Microbes & Infections2021-01-0113 citations

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

New England Journal of Medicine2020-10-281414 citations